ReviewCentral European journal of urology2024
Differential performance of imaging modalities predicting pathological response to neoadjuvant chemotherapy in urothelial bladder cancer: a systematic review and meta-analysis.
Review in Central European journal of urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: We assessed the differential performance of imaging modalities predicting pathological response to neoadjuvant chemotherapy (NAC) in urothelial bladder cancer (UBC). Material and methods: Literature search was conducted using the MEDLINE, SCOPUS, and Cochrane Library in December 2023 to identify eligible studies. Results: Twenty-two studies comprising 1085 patients were selected. The pooled diagnostic odds ratio (DOR), positive likelihood ratio (LR), and negative LR of FDG positron emission tomography-computed tomography (PET/CT) for predicting bladder tumor complete pathological response (CPR) were 17.33 (95% CI: 1.65-180.99), 2.80 (95% CI: 1.04-7.57), and 0.16 (95% CI: 0.02-0.90), respectively. The pooled DOR, positive LR, and negative LR of FDG- PET/CT for predicting lymph node CPR were 5.25 (95% CI: 2.77-9.93), 1.62 (95% CI: 1.20-2.19), and 0.30 (95% CI: 0.22-0.43), respectively. The pooled DOR, positive LR, and negative LR of contrast enhanced magnetic resonance imaging (CEMRI) for predicting bladder tumor CPR were 153 (95% CI: 26.29-890.1), 16.20 (95% CI: 4.19-62.54), and 0.10 (95% CI: 0.04-0.26), respectively. The pooled DOR, positive LR, and negative LR of CEMRI for predicting lymph node CPR were 13.33 (95% CI: 1.06-166.37), 5.62 (95% CI: 0.82-38.53), and 0.42 (95% CI: 0.16-1.06), respectively. Conclusions: We demonstrated that CEMRI (including mpMRI) helps accurate assessment of response to NAC in UBC. While CEMRI is a useful tool to detect residual tumor in lymph nodes, contrast enhanced CT scan and FDG-PET/CT are precise staging modality to identify nodal metastasis responders to NAC. Nevertheless, this differential diagnostic performance needs to be further refined with radiomics and novel tracers to help individualized clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.